Thyroid Dysfunction and Its Association With Metabolic Dysfunction-Associated Fatty Liver Disease
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Fibroscan.
- Who it may be relevant to
- Registry conditions: Thyroid Dysfunction, Metabolic Dysfunction-Associated Fatty Liver Disease. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
This study aims to evaluate the prevalence of thyroid dysfunction and its association with metabolic dysfunction-associated fatty liver disease.
Detailed description
One of the most common causes of chronic liver diseases worldwide is metabolic dysfunction-associated fatty liver disease (MAFLD), which affects about 30% of adults. Thyroid hormones are critical in maintaining metabolic homeostasis throughout life and are intimately linked to the liver.
Dysfunctions of the thyroid gland have been implicated as one of the most important risk factors of MAFLD due to its important role in the hepatic synthesis of fatty acid and cholesterol. Maintaining liver metabolism requires thyroid function to be normal, while thyroid disorders may lead to liver disease progression.
Interventions
- Device Fibroscan
Fibroscan will be used to assess the stages of fibrosis and steatosis using Dimensional ultrasound TE (transient elastography). Dimensional ultrasound TE (transient elastography) will be used for staging liver fibrosis and steatosis by measuring the velocity of a low frequency (50 Hz) elastic shear wave propagating through the liver.
Primary outcome measures
- Level of free triiodothyronine (FT3) [Time frame: After the sample is taken (up to 5 minutes)]
Secondary outcome measures (4)
- Level of free thyroxine (FT4) [Time frame: After the sample is taken (up to 5 minutes)]
- Level of thyroid stimulating hormone [Time frame: After the sample is taken (up to 5 minutes)]
- Relation between gender and thyroid function [Time frame: After the sample is taken (up to 5 minutes)]
- Correlation between metabolic data and thyroid function tests [Time frame: After the sample is taken (up to 5 minutes)]
Eligibility criteria
Inclusion criteria
- Age ≥ 18 years.
- Both sexes.
- Patients with metabolic dysfunction-associated fatty liver disease (MAFLD).
Exclusion criteria
- History of thyroid disease or treatment (e.g., thyroid nodules, thyroid cancer, hypothyroidism, and hyperthyroidism).
- Patients with alcoholic liver disease take more than 40g of alcohol (or four units) per day.
- Viral hepatitis.
- Pregnant women.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Case-control
Study locations
Egypt · 1 center
- Tanta University — Tanta
Identifiers
NCT: NCT06739330 · 36264PR929/11/24